Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

in 2009.

As of March 31, 2009, Oncothyreon's cash and cash equivalents were $15.4 million, compared to $19.2 million at the end of 2008, a decrease of $3.8 million, or 19.8 percent. Major contributors to the net change included $2.1 million used in operations in the quarter and a decrease in accounts payable and accrued liabilities of $1.7 million.

Financial Guidance

Oncothyreon believes the following financial guidance to be correct as of the date provided. The Company is providing this guidance as a convenience to investors and assumes no obligation to update it.

Expenses in 2009 are expected to be substantially less than in 2008, primarily as a result of transferring manufacturing and process development activities for Stimuvax to Merck KGaA and of the previously announced plan to restrict development activities to PX-478 and PX-866. Oncothyreon currently expects cash used in operations in 2009 to be approximately $12 million. As a result, Oncothyreon estimates that the Company's existing cash, together with a milestone payment from Merck KGaA expected at year end, will be sufficient to fund operations for at least the next twelve (12) months.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide Oncothyreon's investors with an understanding of our current results and future prospects, this release may contain statements that are forward-looking. Any statements contained in this press release that are not statements of hi
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vala ... the U.S. Environmental Protection Agency (EPA). This new ... developmental toxicity models, including tests designed to assess ... and the formation of connections between neurons (synapses), ... neurodifferentiation and synapse formation by environmental pollutants likely ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
(Date:7/29/2014)... MA (PRWEB) July 30, 2014 ... (UC) and collaboration company, is proud to announce ... account management positions in their Boston, Charleston and ... response to the increased demand for hosted solutions, ... operational efficiency and reduce cost. , SoundConnect was ...
(Date:7/29/2014)... hurdled a number of significant technological challenges in ... technology originally created for the James Webb Space ... Harvey Moseley, a scientist at NASA,s Goddard Space ... electrostatically actuated microshutter arrays that is, those ... as functional as the current technology,s magnetically activated ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3SoundConnect Organization and Culture is Evolving 2Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4
... PRINCETON, N.J., TOKYO, and REDWOOD CITY, Calif., March ... Inc. (Nasdaq: PDLI ) today announced the ... has acquired PDL,s,rights to IV Busulfex(R) (busulfan), including ... million plus inventory,value., IV Busulfex is an ...
... Calif., March 10 Cepheid (Nasdaq:,CPHD) will present ... March 18 at 10:15 a.m. ET at The ... Chief Executive Officer, will provide a corporate overview., ... may be,accessed on Cepheid,s Web site at ...
... late 2007 ... ... prescribing information for PROCRIT(R) (Epoetin alfa),following guidance from the U.S. Food and ... class., Modifications to the label were based on an unplanned interim ...
Cached Biology Technology:Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 2Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 3Otsuka Pharmaceutical and PDL BioPharma Close Sale of IV Busulfex 4Cepheid to Present at Cowen and Company's 28th Annual Healthcare Conference 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 2Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 3Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 4Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 5Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 6Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) 7
(Date:7/30/2014)... better decisions about what they eat, the Food and ... to the Nutrition Facts label found on nearly every ... Chemical & Engineering News (C&EN), the weekly news ... updates and the fight that has ensued. , ... that while the Nutrition Facts label has remained largely ...
(Date:7/30/2014)... is a subject of major interest in neuroscience. ... during the distinct stages of Wallerian degeneration: transcription ... dedifferentiation. Although gene expression responses in the distal ... injury are known, differences in gene expression between ... Dengbing Yao and co-workers from Nantong University, China ...
(Date:7/30/2014)... JOSE, Calif. , July 30, 2014 /PRNewswire/ ... partnership with the United States Air Force Research ... proposed by Binghamton University ... human performance monitoring (HPM). The $425,000 project, with ... electronics packaging firm i3 Electronics, Inc. ( ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 2Nano-Bio Manufacturing Consortium Awards Funding to Binghamton University for Development of Electronics and Biometric Sensor Platforms 3
... could see humble cotton thread emerge as a core ... such as kidney failure and diabetes. In a ... and sewing needles to literally stitch,together the uniquely low-cost ... postage stamp. Microfluidic analytical devices, which have been ...
... University of Wisconsin-Madison engineers has developed a highly ... a biomass derivative, into the chemical equivalent of ... 95 percent of the energy from the original ... dioxide under high pressure for future beneficial use. ...
... new University of Colorado at Boulder study shows mice ... with a deadly and poorly understood human inflammatory disease, ... The human disease, known as Hemophagocytic Lymphohistiocytosis, or HLH, ... percent and 90 percent of its victims, said Diane ...
Cached Biology News:How long is a piece of thread? Long enough to save a life 2New process yields high-energy-density, plant-based transportation fuel 2New University of Colorado paper shows novel way to study human inflammatory disease 2
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... Signal Enhancer does for enzyme-/substrate-based blotting what intensifying ... the signal up to 10-fold (or one order ... Western Blot Signal Enhancer membrane treatment is a ... to your current Western blotting protocol. The result ...
... multi-functional program that searches for ... sequence file for polymerase chain ... mutagenesis, and various hybridization applications. ... secondary structure of oligonucleotides based ...
...
Biology Products: